Health Care System
Hospitals, including those participating in the 340B Drug Pricing Program, are the true safety-net, not the pharmaceutical industry with its 鈥渟kyrocketing prescription drug prices and huge profits,鈥 AHA Executive Vice President Tom Nickels writes in an AHASTAT blog post today.
A recent proposal that calls for reducing the benefits of the 340B Drug Pricing Program to curb rapidly rising prescription drug costs is 鈥渕isguided,鈥 writes AHA Executive Vice President Tom Nickels in an AHASTAT blog post today.
The rapidly rising costs of prescription drugs is causing significant financial challenges for patients and their care providers.
Many groups, including the AHA, are evaluating options for addressing this important issue. However, one recent proposal, which is seriously misguided, would reduce a鈥
The AHA today released a webinar on its 2016 Environmental Scan, which provides a national high-level perspective on the health care landscape and market forces that have a high probability of affecting hospitals and health systems. Topics range from consumers and patients to political issues and鈥
The AHA last week criticized as 鈥渕isdirected鈥 and a blow to patient care the Medicare Payment Assessment Commission鈥檚 (MedPAC) recommendation that Congress reduce Part B drug payment rates to hospitals participating in the 340B Drug Pricing Program.
At its Jan. 14 meeting, the commission voted 14鈥
The AHA today urged the Medicare Payment Advisory Commission to withdraw its draft recommendation to reduce Part B drug payment rates to hospitals participating in the 340B Drug Pricing Program. 鈥淭his recommendation is outside of the scope of MedPAC鈥檚 mission, lacks a clear purpose and penalizes鈥
This infographic PDF urges Congress to preserve the 340B program to protect access to care.